Atyr PHARMA (ATYR) Competitors $3.34 -0.13 (-3.75%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$3.38 +0.04 (+1.08%) As of 05/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. AMPH, SNDX, ADPT, BGM, AUPH, ETNB, WVE, XFOR, ELVN, and COLLShould you be buying Atyr PHARMA stock or one of its competitors? The main competitors of Atyr PHARMA include Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Adaptive Biotechnologies (ADPT), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), 89bio (ETNB), Wave Life Sciences (WVE), X4 Pharmaceuticals (XFOR), Enliven Therapeutics (ELVN), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Atyr PHARMA vs. Amphastar Pharmaceuticals Syndax Pharmaceuticals Adaptive Biotechnologies Qilian International Holding Group Aurinia Pharmaceuticals 89bio Wave Life Sciences X4 Pharmaceuticals Enliven Therapeutics Collegium Pharmaceutical Atyr PHARMA (NASDAQ:ATYR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk. Do insiders & institutionals have more ownership in ATYR or AMPH? 61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate ATYR or AMPH? Atyr PHARMA currently has a consensus target price of $18.60, indicating a potential upside of 456.89%. Amphastar Pharmaceuticals has a consensus target price of $43.50, indicating a potential upside of 82.16%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts plainly believe Atyr PHARMA is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, ATYR or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$235K1,262.93-$50.39M-$0.87-3.84Amphastar Pharmaceuticals$731.97M1.55$137.54M$3.067.80 Does the media refer more to ATYR or AMPH? In the previous week, Atyr PHARMA had 4 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 9 mentions for Atyr PHARMA and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.26 beat Atyr PHARMA's score of 0.79 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ATYR or AMPH? Amphastar Pharmaceuticals received 379 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 65.88% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes13100.00% Underperform VotesNo VotesAmphastar PharmaceuticalsOutperform Votes39265.88% Underperform Votes20334.12% Is ATYR or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Atyr PHARMA's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Amphastar Pharmaceuticals 21.80%26.44%11.89% Which has more volatility and risk, ATYR or AMPH? Atyr PHARMA has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. SummaryAmphastar Pharmaceuticals beats Atyr PHARMA on 11 of the 19 factors compared between the two stocks. Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricAtyr PHARMABiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$296.79M$2.95B$5.54B$7.93BDividend YieldN/A1.89%5.09%4.23%P/E Ratio-3.5530.0722.5318.54Price / Sales1,262.93494.82399.57103.29Price / CashN/A168.6838.1834.62Price / Book2.173.176.774.25Net Income-$50.39M-$72.35M$3.22B$248.18M7 Day Performance-0.30%2.14%1.11%0.91%1 Month Performance12.84%5.67%2.50%2.58%1 Year PerformanceN/A-23.57%15.76%4.02% Atyr PHARMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRAtyr PHARMA2.5564 of 5 stars$3.34-3.7%$18.60+456.9%N/A$296.79M$235,000.00-3.5553Short Interest ↑AMPHAmphastar Pharmaceuticals4.4324 of 5 stars$24.41+0.9%$43.50+78.2%-43.3%$1.16B$731.97M8.141,620Upcoming EarningsPositive NewsSNDXSyndax Pharmaceuticals3.6451 of 5 stars$13.42+0.7%$36.20+169.7%-37.1%$1.15B$23.68M-3.70110Upcoming EarningsPositive NewsADPTAdaptive Biotechnologies4.1405 of 5 stars$7.77-1.6%$9.40+21.0%+163.8%$1.15B$178.96M-7.13790Earnings ReportNews CoveragePositive NewsBGMQilian International Holding GroupN/A$11.27+1.6%N/AN/A$1.10B$25.10M0.00298AUPHAurinia Pharmaceuticals2.6539 of 5 stars$8.00-2.2%$11.50+43.8%+57.7%$1.09B$235.13M-53.33300ETNB89bio2.9742 of 5 stars$7.40+6.6%$27.25+268.2%-7.1%$1.08BN/A-2.5440Earnings ReportUpcoming EarningsAnalyst UpgradeNews CoveragePositive NewsWVEWave Life Sciences4.313 of 5 stars$6.83+1.5%$22.18+224.8%+40.0%$1.05B$108.30M-6.15240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageXFORX4 Pharmaceuticals3.8459 of 5 stars$5.34-6.3%$85.00+1,491.8%-88.7%$927.36M$2.56M-59.3380Stock SplitNews CoverageGap DownHigh Trading VolumeELVNEnliven Therapeutics2.2534 of 5 stars$18.91+3.8%$40.33+113.3%+9.7%$926.67MN/A-9.9550News CoveragePositive NewsGap DownCOLLCollegium Pharmaceutical4.0414 of 5 stars$26.87+0.3%$43.60+62.3%-28.4%$904.19M$631.45M11.58210Upcoming EarningsPositive News Related Companies and Tools Related Companies Amphastar Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Qilian International Holding Group Alternatives Aurinia Pharmaceuticals Alternatives 89bio Alternatives Wave Life Sciences Alternatives X4 Pharmaceuticals Alternatives Enliven Therapeutics Alternatives Collegium Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
